Acasti Pharma Other Operating Income or Expenses 2014-2024 | GRCE
Acasti Pharma other operating income or expenses from 2014 to 2024. Other operating income or expenses can be defined as the aggregate amount of all operating expenses either too small to report separately or that cannot be standardized into another Zacks field.
Acasti Pharma Annual Other Operating Income or Expenses
(Millions of US $) |
| 2024 |
$ |
| 2023 |
$-34 |
| 2022 |
$-0 |
| 2021 |
$-6 |
| 2020 |
$ |
| 2019 |
$ |
| 2018 |
$ |
| 2017 |
$ |
| 2016 |
$ |
| 2015 |
$ |
| 2015 |
$ |
| 2014 |
$ |
| 2014 |
$ |
| 2013 |
$ |
| 2013 |
$ |
Acasti Pharma Quarterly Other Operating Income or Expenses
(Millions of US $) |
| 2024-06-30 |
|
| 2024-03-31 |
|
| 2023-12-31 |
|
| 2023-09-30 |
|
| 2023-06-30 |
|
| 2023-03-31 |
|
| 2022-12-31 |
|
| 2022-09-30 |
|
| 2022-06-30 |
|
| 2022-03-31 |
|
| 2021-12-31 |
$-0 |
| 2021-09-30 |
|
| 2021-06-30 |
|
| 2021-03-31 |
$-0 |
| 2020-12-31 |
|
| 2020-09-30 |
$-5 |
| 2020-06-30 |
|
| 2020-03-31 |
|
| 2019-12-31 |
|
| 2019-09-30 |
|
| 2019-06-30 |
|
| 2019-03-31 |
|
| 2018-12-31 |
|
| 2018-09-30 |
|
| 2018-06-30 |
|
| 2018-03-31 |
|
| 2017-12-31 |
|
| 2017-09-30 |
|
| 2017-06-30 |
|
| 2017-02-28 |
|
| 2016-11-30 |
|
| 2016-08-31 |
|
| 2016-05-31 |
|
| 2016-03-31 |
|
| 2016-02-29 |
|
| 2015-12-31 |
|
| 2015-09-30 |
|
| 2015-06-30 |
|
| 2015-03-31 |
|
| 2014-12-31 |
|
| 2014-09-30 |
|
| 2014-06-30 |
|
| 2014-03-31 |
|
| 2014-02-28 |
|
| 2013-12-31 |
|
| 2013-09-30 |
|
| 2013-06-30 |
|
| 2013-03-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-GENERIC DRG |
$0.033B |
$0.000B |
|
Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada.
|
